RE GEN RXStart a visit
PeptidesSexual healthDermatology

RE GEN RX · compounded peptides

Compounded peptides — with the legal basis for every one.

Peptide therapy is the fastest-moving corner of compounding, and the most confused. RE GEN only requests a peptide where a documented §503A basis exists — and we will show you that basis. Research-chemical shops cannot. A real Illinois practice, filling through a licensed 503A pharmacy.

See the peptide menu →Start a visitBook a consult · $49

Legal-basis grid updated July 2026 · from-prices plus shipping · a clinician still decides

Products sold online as “research peptides,” clinic vials of uncertain origin, and shifting FDA guidance have left people unsure what a pharmacy can lawfully prepare. We only request a peptide where a documented legal basis exists — and we will not request a substance that lacks a lawful pathway, no matter the demand.

◆ Licensed 503A compounding · patient-specific · sterile & potency-tested

How peptide compounding is actually regulated

Two gates decide whether a peptide is compoundable.

Most of the noise comes from one misconception: that anything “not on FDA’s safety list” is fair game. It isn’t. Compounding needs an affirmative basis, not the mere absence of a prohibition.

Gate 1 · §503A(b)(1)(A)

Is the bulk substance eligible?

A pharmacy may compound from a bulk drug substance only if it meets one of three conditions:

  • →It has an applicable USP/NF monograph, or
  • →It is a component of an FDA-approved drug, or
  • →It appears on FDA’s 503A bulks list.

Meets none of these? There is no lawful pathway — regardless of demand or how it is marketed elsewhere. Category 3 (nominated without adequate support) gets no enforcement discretion.

Gate 2 · the “essentially a copy” rule

Is the finished preparation permissible?

Even when a bulk substance is eligible, a compounded preparation cannot be “essentially a copy” of a commercially available drug — without a documented, patient-specific clinical difference.

  • →This matters for any peptide that mirrors an approved drug (for example tesamorelin or bremelanotide).
  • →A different strength, form, route, or a removed allergen can establish the clinical difference.
  • →The rationale is documented per patient — not assumed.

Eligible from bulk and permissible as a finished product are two separate questions. Both gates must be satisfied.

Where the major peptides stand · 2026

The straight answer, peptide by peptide.

This is the grid RE GEN uses. Status can change as FDA acts — we confirm the current basis before a prescription is sent. Peptides without a lawful pathway are not orderable.

PeptidesStatusBasis / notes
Sermorelin, Tesamorelin, PT-141 (Bremelanotide)✓ Lawful pathwayComponent of an FDA-approved drug. The finished compound still has to clear the “essentially a copy” rule with a documented, patient-specific clinical difference.
Oxytocin, Glutathione, VIP, topical GHK-Cu✓ Lawful pathwayMonograph / 503A bulks-list framework. Route limits can apply — GHK-Cu is eligible for non-injectable (e.g. topical) routes only.
BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon◷ Under reviewNo lawful §503A pathway yet. FDA’s Pharmacy Compounding Advisory Committee recommended these for the 503A bulks list (July 2026). Waiting on FDA action and rulemaking — a vote is not a green light.
Emideltide (DSIP)✕ No pathwayReviewed by PCAC in July 2026 and not recommended.
CJC-1295, Ipamorelin, Thymosin Alpha-1, MK-677, Kisspeptin, GHRP-2/6, Melanotan✕ No pathwayNot nominated / safety category. No lawful §503A pathway at this time.

§503A is patient-specific compounding by a pharmacy; §503B is outsourcing facilities. Bulk-eligibility rules differ. The statuses above address §503A. As of January 7, 2025, FDA stopped sorting newly nominated substances into interim categories — new substances now move toward PCAC review and bulks-list rulemaking.

The clearest path peptides have had — but not a green light.

On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides for the 503A bulks list and voted to recommend six. That is a step — not approval.

BPC-157 · Jul 23

✓ Recommended

KPV · Jul 23

✓ Recommended

TB-500 · Jul 23

✓ Recommended

MOTS-c · Jul 23

✓ Recommended

Semax · Jul 24

✓ Recommended

Epitalon · Jul 24

✓ Recommended

Emideltide (DSIP) · Jul 24

✕ Not recommended

Why a recommendation isn’t “available”

  1. 1 · PCAC only advises. It reviews the data and recommends. FDA then decides.
  2. 2 · Listing requires rulemaking. Even a favorable outcome still needs formal bulks-list placement.
  3. 3 · The copy rule still applies. Eligibility from bulk does not override the “essentially a copy” gate.
  4. ✓ We add on confirmation, not on a vote. If FDA lists a peptide or issues written discretion, we will add it — with its documented basis, and not before.

Bottom line: the compounding status of those six has not changed — they are not orderable today. What changed is a realistic path forward, pending FDA action. The live catalog is the source of truth for what RE GEN can send.

Read the science — not a sales page.

For peptides we actually carry, start with our education hub. Claims should be cited, not asserted. RE GEN will not promise outcomes.

RE GEN peptide educationSafety & compounding

Request what’s carried — Illinois clinician first.

Patients start a visit with RE GEN. A licensed Illinois clinician decides. If a peptide is appropriate and a licensed 503A pharmacy can lawfully compound it, you pay the invoice and it ships. If it is not carried, it is not available — regardless of the noise online.

  • ✓ Intake in minutes — then pay only if prescribed (or we refund).
  • ✓ Ask whether a peptide is even compoundable yet. We will tell you no.
  • ✓ Catalog is the source of truth. No gray-market vials.
Start at tryregenrx.com/start

How we answer it

Can you compound BPC-157 for me?

Not yet. BPC-157 has no lawful §503A pathway today. FDA’s advisory committee recommended it for the bulks list in July 2026, but FDA has not acted, so it cannot be compounded. If the goal is recovery support, we can show you what is currently carried and its legal basis — then a licensed Illinois clinician decides if any of it is right for you.

RE GEN RX · regulatory status as of July 2026 · confirm before prescribing · not legal or medical advice

Illinois practice · licensed 503A compounding

Illinois clinician first. A licensed 503A pharmacy fills what they prescribe.

Hello Gorgeous PC · 74 W. Washington St, Oswego, IL
RE GEN desk 630-636-6193

Start a visit, a licensed Illinois clinician reviews, then you pay the invoice. If they don't prescribe, we refund.

Start a visitBook a consult · $49

Educational information for Illinois patients. Not a substitute for independent clinical judgment. Compounded medications are prepared by a US-licensed 503A compounding pharmacy and are not FDA-approved. A request is a consult — not a guaranteed prescription. RE GEN RX is the prescription door of Hello Gorgeous Med Spa (Hello Gorgeous PC), Oswego, Illinois.